The Emergence of Human Pathogenic Coronaviruses: Lectins as Antivirals for SARS-CoV-2

Author(s): Sayed S. Sohrab*, Mohd. Suhail, Mohammad A. Kamal, Fahim Ahmad, Esam I. Azhar

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 41 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Human coronaviruses (HCoV) are common viruses and known to be associated with respiratory diseases, including pneumonia. Currently, seven human coronaviruses have been identified and known to cause upper and lower respiratory infections as well as nosocomial viral infections in humans. The bats, palm civets, and camels are identified as the reservoir of human coronaviruses. In 2002-2003, the emergence of SARS-CoV resulted in an outbreak and led towards the more awareness and importance of scientific research and medical urgency.

Methods: The recently identified SARS-CoV-2 was identified from the seafood market of the city Wuhan, China, in December 2019 and caused a global pandemic. This virus has now spread to more than 213 countries. This is the third highly pathogenic human coronavirus after SARS and MERS-CoV. The coronaviruses have RNA as genetic material and are known to have frequent recombination and mutations in their genome, which lead to the emergence and re-emergence of new virus strains and isolates with novel properties and extended hosts. The genetic mutations and suitable environmental conditions result in the emergence and re-emergence of pathogenic coronaviruses and cause a serious issue to human health and the economy globally. Lectins are the ubiquitous group of proteins that bind to glycosylated molecules.

Conclusion: The plant lectins are known to have significant antiviral activities against coronaviruses. Additionally, the plant lectins can be used as potential therapeutics against bacteria, fungus, yeast, and protozoa. In this review, we have discussed the current status of human pathogenic coronavirus emergence and the use of plant lectins as antivirals against SARS-CoV-2.

Keywords: Emergence, coronaviruses, SARS-CoV-2, natural products, antivirals, lectins, inhibitors.

[1]
Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 1997; 48: 1-100.
[http://dx.doi.org/10.1016/S0065-3527(08)60286-9] [PMID: 9233431]
[2]
Cheng VCC, Lau SKP, Woo PCY, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20(4): 660-94.
[http://dx.doi.org/10.1128/CMR.00023-07] [PMID: 17934078]
[3]
Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[4]
WHO. Coronavirus disease 2019 (COVID-19) Situation Report -59. 2019. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200319-sitrep-59-covid-19.pdf? sfvrsn=c3dcdef9_2
[5]
Worldometer.. Available at: https://www.worldometers.info/coronavirus/
[6]
Leibowitz JL. Coronaviruses: Molecular and Cellular Biology. Emerg Infect Dis 2008; 14(4): 693-4.
[http://dx.doi.org/10.3201/eid1404.080016]
[7]
Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3): 181-92.
[http://dx.doi.org/10.1038/s41579-018-0118-9] [PMID: 30531947]
[8]
Mitchell CA, Ramessar K, O’Keefe BR. Antiviral lectins: Selective inhibitors of viral entry. Antiviral Res 2017; 142: 37-54.
[http://dx.doi.org/10.1016/j.antiviral.2017.03.007] [PMID: 28322922]
[9]
Lusvarghi S, Bewley CA. Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses 2016; 8(10)E296
[http://dx.doi.org/10.3390/v8100296] [PMID: 27783038]
[10]
Woodrum BW, Maxwell J, Allen DM, et al. A Designed “Nested” Dimer of Cyanovirin-N Increases Antiviral Activity. Viruses 2016; 8(6)E158
[http://dx.doi.org/10.3390/v8060158] [PMID: 27275831]
[11]
Millet JK, Séron K, Labitt RN, et al. Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. Antiviral Res 2016; 133: 1-8.
[http://dx.doi.org/10.1016/j.antiviral.2016.07.011] [PMID: 27424494]
[12]
Mazalovska M, Kouokam JC. Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections. BioMed Res Int 2018.20183750646
[http://dx.doi.org/10.1155/2018/3750646] [PMID: 29854749]
[13]
Li L, Yu X, Zhang H, et al. In vitro antiviral activity of Griffithsin against porcine epidemic diarrhea virus. Virus Genes 2019; 55(2): 174-81.
[http://dx.doi.org/10.1007/s11262-019-01633-7] [PMID: 30637608]
[14]
Covés-Datson EM, Dyall J, DeWald LE, et al. Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin. PLoS Negl Trop Dis 2019; 13(7)e0007595
[http://dx.doi.org/10.1371/journal.pntd.0007595] [PMID: 31356611]
[15]
Mani JS, Johnson JB, Steel JC, et al. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res 2020.284197989
[http://dx.doi.org/10.1016/j.virusres.2020.197989] [PMID: 32360300]
[16]
Boyd WC, Shapleigh E. Specific Precipitating Activity of Plant Agglutinins (Lectins). Science 1954; 119(3091): 419.
[http://dx.doi.org/10.1126/science.119.3091.419] [PMID: 17842730]
[17]
Santos AF, Da Silva MD, Napoleão TH, Paiva PM, Correia MD, Coelho LC. Lectins: Function, structure, biological properties andpotential applications
[18]
Aranda-Souza MA, Rossato FA. A lectin from Bothrops leucurus snake venom raises cytosolic calcium levels and promotes B16-F10 melanoma necrotic cell death via mitochondrial permeability transition Web of Science 2014.
[19]
Wallis R. Interactions between mannose-binding lectin and MASPs during complement activation by the lectin pathway. Immunobiology 2007; 212(4-5): 289-99.
[http://dx.doi.org/10.1016/j.imbio.2006.11.004] [PMID: 17544814]
[20]
Krupovic M, Cvirkaite-Krupovic V, Bamford DH. Protein A33 responsible for antibody-resistant spread of Vaccinia virus is homologous to C-type lectin-like proteins. Virus Res 2010; 151(1): 97-101.
[http://dx.doi.org/10.1016/j.virusres.2010.03.004] [PMID: 20302896]
[21]
Francis F, Jaber K, Colinet F, Portetelle D, Haubruge E. Purification of a new fungal mannose-specific lectin from Penicillium chrysogenum and its aphicidal properties. Fungal Biol 2011; 115(11): 1093-9.
[http://dx.doi.org/10.1016/j.funbio.2011.06.010] [PMID: 22036288]
[22]
Wong ACP, Li X, Lau SKP, Woo PCY. Global Epidemiology of Bat Coronaviruses. Viruses 2019; 11(2)E174
[http://dx.doi.org/10.3390/v11020174] [PMID: 30791586]
[23]
Ge X-Y, Li J-L, Yang X-L, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013; 503(7477): 535-8.
[http://dx.doi.org/10.1038/nature12711] [PMID: 24172901]
[24]
Lau SKP, Woo PCY, Yip CCY, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol 2006; 44(6): 2063-71.
[http://dx.doi.org/10.1128/JCM.02614-05] [PMID: 16757599]
[25]
Vabret A, Dina J, Gouarin S, Petitjean J, Corbet S, Freymuth F. Detection of the new human coronavirus HKU1: a report of 6 cases. Clin Infect Dis 2006; 42(5): 634-9.
[http://dx.doi.org/10.1086/500136] [PMID: 16447108]
[26]
Lim YX, Ng YL, Tam JP, Liu DX. Human Coronaviruses: A Review of Virus-Host Interactions. Diseases 2016; 4(3)E26
[http://dx.doi.org/10.3390/diseases4030026] [PMID: 28933406]
[27]
Abdul-Rasool S, Fielding BC. Understanding Human Coronavirus HCoV-NL63. Open Virol J 2010; 4: 76-84.
[http://dx.doi.org/10.2174/1874357901004010076] [PMID: 20700397]
[28]
van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10(4): 368-73.
[http://dx.doi.org/10.1038/nm1024] [PMID: 15034574]
[29]
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1] [PMID: 25720466]
[30]
Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human Coronaviruses. Adv Virus Res 2018; 100: 163-88.
[http://dx.doi.org/10.1016/bs.aivir.2018.01.001] [PMID: 29551135]
[31]
Sabir JSM, Lam TTY, Ahmed MMM, et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 2016; 351(6268): 81-4.
[http://dx.doi.org/10.1126/science.aac8608] [PMID: 26678874]
[32]
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814-20.
[http://dx.doi.org/10.1056/NEJMoa1211721] [PMID: 23075143]
[33]
Azhar EI, Hashem AM, El-Kafrawy SA, et al. Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient. MBio 2014; 5(4): e01450-14.
[http://dx.doi.org/10.1128/mBio.01450-14] [PMID: 25053787]
[34]
Lam TT-Y, Jia N, Zhang Y-W, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020; 583(7815): 282-5.
[http://dx.doi.org/10.1038/s41586-020-2169-0] [PMID: 32218527]
[35]
Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci 2020; 63(3): 457-60.
[http://dx.doi.org/10.1007/s11427-020-1637-5] [PMID: 32009228]
[36]
Kan B, Wang M, Jing H, et al. Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol 2005; 79(18): 11892-900.
[http://dx.doi.org/10.1128/JVI.79.18.11892-11900.2005] [PMID: 16140765]
[37]
Che XY, Di B, Zhao GP, et al. A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis 2006; 43(1): e1-5.
[http://dx.doi.org/10.1086/504943] [PMID: 16758408]
[38]
Pm dS, Mc dM, Fs G, D dST, Ap SdO, Gsv dM, et al. PgTeL, the lectin found in Punica granatum juice, is an antifungal agent against Candida albicans and Candida krusei International journal of biological macromolecules 2018.
[39]
Ramos EL, Santana SS, Silva MV, Santiago FM, Mineo TW, Mineo JR. Leandro Peixoto Ferreira de Souza. Lectins from Synadenium carinatum (ScLL) and Artocarpus heterophyllus (ArtinM) Are Able to Induce Beneficial Immunomodulatory Effects in a Murine Model for Treatment of Toxoplasma gondii Infection. Front Cell Infect Microbiol 2016; 6: 164.
[http://dx.doi.org/10.3389/fcimb.2016.00164] [PMID: 27933277]
[40]
Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov 2014; 4(11): 1310-25.
[http://dx.doi.org/10.1158/2159-8290.CD-13-1010] [PMID: 25122198]
[41]
Azimi A. TMPRSS2 inhibitors, Bromhexine, Aprotinin, Camostat and Nafamostat as potential treatments for COVID-19 Frenxiv. 2020. Available at: https://frenxiv.org/a3rvm/
[42]
Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov 2020; 10(6): 779-82.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0451] [PMID: 32276929]
[43]
Jankun J. COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs. Translation. University of Toledo Journal of Medical Sciences 2020; 7: 1-5.
[44]
McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 2020.157104859
[http://dx.doi.org/10.1016/j.phrs.2020.104859] [PMID: 32360480]
[45]
Liu M, Wang T, Zhou Y, Zhao Y, Zhang Y, Li J. Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management. J Transl Int Med 2020; 8(1): 9-19.
[http://dx.doi.org/10.2478/jtim-2020-0003] [PMID: 32435607]
[46]
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71(15): 732-9.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[47]
Fan H-H, Wang L-Q, Liu W-L, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl) 2020; 133(9): 1051-6.
[http://dx.doi.org/10.1097/CM9.0000000000000797] [PMID: 32149769]
[48]
Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell 2020; 181(4): 905-913. e7.
[http://dx.doi.org/10.1016/j.cell.2020.04.004] [PMID: 32333836]
[49]
Keyaerts E, Vijgen L, Pannecouque C, et al. Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle. Antiviral Res 2007; 75(3): 179-87.
[http://dx.doi.org/10.1016/j.antiviral.2007.03.003] [PMID: 17428553]
[50]
Michelow IC, Lear C, Scully C, et al. High-dose mannose-binding lectin therapy for Ebola virus infection. J Infect Dis 2011; 203(2): 175-9.
[http://dx.doi.org/10.1093/infdis/jiq025] [PMID: 21288816]
[51]
Kumaki Y, Wandersee MK, Smith AJ, et al. Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Res 2011; 90(1): 22-32.
[http://dx.doi.org/10.1016/j.antiviral.2011.02.003] [PMID: 21338626]
[52]
Covés-Datson EM, King SR, Legendre M, et al. A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection in vivo. Proc Natl Acad Sci USA 2020; 117(4): 2122-32.
[http://dx.doi.org/10.1073/pnas.1915152117] [PMID: 31932446]
[53]
Hwang H-J, Han J-W, Jeon H, et al. Characterization of a Novel Mannose-Binding Lectin with Antiviral Activities from Red Alga, Grateloupia chiangii. Biomolecules 2020; 10(2)E333
[http://dx.doi.org/10.3390/biom10020333] [PMID: 32092955]
[54]
Petersen KA, Matthiesen F, Agger T, et al. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol 2006; 26(5): 465-75.
[http://dx.doi.org/10.1007/s10875-006-9037-z] [PMID: 16990992]
[55]
WHO. A Coordinated Global Research Roadmap: 2019 novel coronavirus 2019. Available at: https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf?ua=1


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 41
Year: 2020
Published on: 21 August, 2020
Page: [5286 - 5292]
Pages: 7
DOI: 10.2174/1381612826666200821120409
Price: $65

Article Metrics

PDF: 25
HTML: 1